samedan logo
 
 
spacer
home > pmps > autumn 2020 > five ways to de-risk new product launches
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Five Ways to De-Risk New Product Launches

Out-licensing their product’s journey to Big Pharma has become the most well-trodden route to market for innovation-led virtual pharmaceutical companies.

By necessity, these small and agile operations have traditionally relied on the resources and expertise of much bigger players to take their products beyond the science, through to marketing, supply chain design, sales, and distribution.

Increasingly, however, virtual pharma operations are exploring ways to take their specialty drugs, biopharmaceuticals, and drug/device combinations to market independently. It’s possible, but it brings entirely new risks and challenges.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christoph Krähenbühl, Senior Director at Excellis Europe, has been involved in serialisation projects since 2006. He has acted as Global Serialisation Project Manager and Product Security Manager at AstraZeneca and as a leading consultant for a breadth of pharma customers. Christoph brings vast practical experience gained from working with clients in all areas of the industry, including leading global pharma companies to contract packers and niche specialised manufacturers, parallel distributors, wholesalers, and industry organisations.
spacer
Christoph Krähenbühl
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Winners of the 2021 CPhI Pharma Awards have now been announced

Milan, 10 November 2021: CPhI Worldwide announces the winners of the 18th edition of the CPhI Pharma Awards, hosted live in Milan, with winners spanning some 10 distinct categories. The Awards seek to recognise ‘Excellence in Pharma’ , assessing entries from the industry leading companies and individuals.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement